Classys booth at the AAD 2026 / Provided by Classys

Classys, a global leader in medical aesthetics, unveiled its aggressive growth strategy for the U.S. market at the American Academy of Dermatology (AAD) annual meeting on Monday.

The company showcased its cutting-edge portfolio at the AAD event in Denver, Colorado, from March 27-31. This included the high-frequency device Everless (marketed as Volnumer in the U.S.), the microneedling radio frequency (RF) system QUADESSY, and previews of their upcoming laser REEPOT and high-intensity focused ultrasound (HIFU) device Ultraformer MPT (known internationally as Shurink Universe).

Building on the successful late-2024 launch of Everless with U.S. partner Cartessa Aesthetics, Classys is swiftly expanding its market presence. The recent introduction of QUADESSY this month marks another milestone. The company aims to complete its core product lineup in the U.S. market this year with the planned releases of REEPOT and Ultraformer MPT, both U.S. Food and Drug Administration (FDA) approved for pigmentation treatment.

A highlight of Classys's AAD presence was a scholarly presentation by leading U.S. dermatologists, showcasing Everless's clinical excellence. This approach, focusing on evidence-based efficacy rather than mere product promotion, resonated strongly with the medical community and underscores Classys's strategy to rapidly solidify its position in the U.S. market.

For Classys, this AAD meeting represents a pivotal moment in its strategy to expand market share in the U.S., a key player in the global energy-based device (EBD) sector. As the company enters its second year in the U.S. market, it plans to accelerate growth through increased sales and marketing investments, portfolio diversification, and a branding approach centered on clinical outcomes.

The U.S. market is our top strategic priority in the global medical aesthetics industry, a Classys spokesperson stated. Leveraging our distinctive portfolio, headlined by Everless and QUADESSY, and backed by robust clinical data, it's poised to rapidly establish the market presence and reinforce the global leadership position.

Classys, a global leader in medical aesthetics, unveiled its aggressive growth strategy fo …

Classys Unveils Aggressive Growth Strategy at AAD 2026: What’s Next for the U.S. Market?